Idifarma
Pharmaceutical CDMO | High Potent Drug Development | Idifarma.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 25 % | 10 % | 1 % | 17 % | 1 % | - | 21 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 20 % | 18 % | 4 % | (6 %) | 4 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 7 % | 4 % | (8 %) | (17 %) | (12 %) | 1 % | 17 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Idifarma, established in 2001 by co-founder Luis Oquiñena, operates as a contract development and manufacturing organization (CDMO) based in Pamplona, Spain. The company provides comprehensive services to the pharmaceutical and biotechnological markets, covering the entire lifecycle of a pharmaceutical product.
The firm's business model is centered on offering a full suite of services, including formulation, analytical development, quality control, and GMP manufacturing for both clinical trials and commercial batches. Idifarma generates revenue by providing these specialized contract services to a global client base, which includes over 100 international pharmaceutical companies. The company's core focus is on the development and manufacturing of niche and highly potent drugs, particularly oral solid dosage forms for oncology.
A significant milestone in Idifarma's history was its acquisition by Ardena, a Belgian CDMO, on September 1, 2021. This acquisition was a strategic move for Ardena to expand its operations into Southern Europe and enhance its capabilities in high-potency drug manufacturing. Before this, in 2016, Suanfarma S.A. acquired a major stake in Idifarma, aiming to boost its international growth, with the co-founders remaining as shareholders and executives. The company had also been supported by local financial investors like Sodena and Caja Rural de Navarra since its early stages.
Idifarma's key services include drug formulation, analytical methods development and validation, stability studies, and regulatory affairs. The company operates from a 40,000-square-foot facility that houses a high-containment plant for manufacturing highly potent drugs. A distinct offering is its expertise in spray drying technology to improve the bioavailability of poorly soluble drugs. In 2021, the company launched 'Simply to Clinic,' an accelerated pathway service designed to take innovative molecules from pre-formulation to clinical trials efficiently.
Keywords: contract development manufacturing organization, CDMO, pharmaceutical services, drug development, GMP manufacturing, highly potent drugs, oncology, oral solid dosage, formulation development, analytical services, spray drying, bioavailability enhancement, clinical trials, quality control, regulatory affairs, Suanfarma, Ardena, Luis Oquiñena, Pamplona, contract manufacturing